Acetylcholine release at cholinergic nerve terminal

“Cholinergic nerve terminal acetylcholine release” refers to the **physiological process** by which the neurotransmitter **acetylcholine** is released from presynaptic terminals of cholinergic neurons. This event is triggered by an influx of calcium ions (Ca\u00b2\u207a) following an action potential. The calcium influx stimulates docking and fusion of synaptic vesicles containing acetylcholine with the presynaptic membrane, leading to exocytosis and subsequent diffusion across the synaptic cleft[1][3][5]. Once in the cleft, acetylcholine binds to postsynaptic receptors—either nicotinic or muscarinic—on target cells such as muscle fibers or other neurons[3][6]. The process is tightly regulated and essential for normal neuromuscular function as well as central nervous system activities like attention and memory[2][4]. Disruption can result in clinical conditions; for example, botulinum toxin inhibits this process causing paralysis while black widow spider venom induces excessive neurotransmitter release leading to muscle spasms[1]. Drugs that inhibit breakdown of released acetylcholine—acetylcholinesterase inhibitors—are used therapeutically in diseases like Alzheimer's but act downstream from this specific step. This entry describes a **process**, not a discrete molecular target such as a receptor or enzyme. Therefore it should not be considered a canonical therapeutic target itself but rather a critical physiological mechanism involving multiple molecular players including choline transporters, choline acetyltransferase, vesicular transporters, SNARE proteins involved in exocytosis, and voltage-gated calcium channels[1][5]. If you are seeking structured information on druggable targets related to this process—for example “Nicotinic acetylcholine receptor,” “Muscarinic acetylcholine receptor,” “Vesicular acetylcholine transporter,” or “Acetyl-CoA transporter”—those would be appropriate canonical entries. > Many toxins are known that interfere with these processes and are effective in preventing ACh secretion. The examples... show botulinum toxin inhibition and black widow spider venom stimulation of ACh release.[1] > Acetylcholine is stored at the end of nerve cells until it’s triggered to be released... Once released... it moves into a space called the synaptic cleft...[3] > The presence of CAT [choline-acetyltransferase] is the 'marker' that a neuron is cholinergic...[1] In summary: “Cholinergic nerve terminal acetylcholine release” describes an essential neurochemical event but does not correspond directly to any single protein or druggable entity; thus it should not be treated as a canonical therapeutic target.

Other names

Cholinergic neurotransmitter releasePresynaptic acetylcholine exocytosisACh release from cholinergic neuron terminals

Inhibition of vesicular acetylcholine release (botulinum toxin blocks synaptic vesicle fusion)[1] Stimulation of excessive acetylcholine release (black widow spider venom causes massive exocytosis)[1]